首页 > 最新文献

ecancermedicalscience最新文献

英文 中文
Comparative efficacy of palliative radiotherapy dose schedules in advanced bladder cancer-associated gross hematuria. 晚期膀胱癌相关性毛细血尿的姑息性放射治疗剂量计划疗效比较。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-06-21 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1718
Kashif Ali Sarwar, Sameed Hussain, Ahsan Mahmood, Zeeshan Ahmed Alvi, Ateeqa Saad

Introduction: Gross hematuria (GH) in advanced/inoperable bladder cancer patients causes significant morbidity. Patients frequently need multiple transfusions. Hypofractionated radiotherapy (RT) has been shown to be effective in symptom palliation. In this study, we explore the efficacy of various fractionation regimens in these patients.

Methods: This single institute retrospective analysis was conducted on 60 consecutive patients treated with palliative RT. Fractionation (single versus multiple) and biologically equivalent doses (BED; high ≥36 Gy versus low <36 Gy) were used to compare the efficacy of various fractionation regimens. The primary outcome was the difference in objective response rate (ORR) between various strata at 2, 4, 8 and 12 weeks. Major secondary outcomes were differences in ORR according to Eastern Cooperative Oncology Group (ECOG) performance status (PS) and tumour node metastases (TNM) stage, and the proportion of patients requiring re-transfusion(s) at 12 weeks. Data were analysed using SPSS 23.

Results: Overall ORR at 2, 4, 8 and 12 weeks was 86%, 77%, 67% and 55%, respectively. There was no statistically significant difference in response rates between single or multi-fraction, or high versus low BED groups (All p = >0.05). Moreover, ECOG PS (p = 0.11) or TNM stage (p = 0.58) also had no impact on the response rate at 12 weeks. Nearly one-third (31%) of patients required further transfusions at 12 weeks.

Conclusion: RT is an effective modality to control GH. No difference in ORR was found between single fractions versus multiple fractions, or high versus low BED regimens. Single fraction RT can be offered to these patients considering low cost, patient convenience and minimal side effects.

导言:晚期/无法手术的膀胱癌患者出现血尿(GH)会导致严重的发病率。患者经常需要多次输血。事实证明,低分次放射治疗(RT)可有效缓解症状。在本研究中,我们探讨了各种分次放疗方案对这些患者的疗效:本研究对 60 例连续接受姑息性 RT 治疗的患者进行了回顾性分析。分次(单次与多次)和生物等效剂量(BED;高剂量≥36 Gy 与低剂量):2周、4周、8周和12周的总体ORR分别为86%、77%、67%和55%。单剂量组与多剂量组、高 BED 组与低 BED 组之间的反应率差异无统计学意义(均 p = >0.05)。此外,ECOG PS(p = 0.11)或 TNM 分期(p = 0.58)对 12 周时的反应率也没有影响。近三分之一(31%)的患者在12周时需要进一步输血:结论:RT是控制GH的有效方法。单次分次与多次分次、高BED方案与低BED方案之间的ORR没有差异。考虑到成本低、患者方便且副作用小,可为这些患者提供单次分次RT治疗。
{"title":"Comparative efficacy of palliative radiotherapy dose schedules in advanced bladder cancer-associated gross hematuria.","authors":"Kashif Ali Sarwar, Sameed Hussain, Ahsan Mahmood, Zeeshan Ahmed Alvi, Ateeqa Saad","doi":"10.3332/ecancer.2024.1718","DOIUrl":"10.3332/ecancer.2024.1718","url":null,"abstract":"<p><strong>Introduction: </strong>Gross hematuria (GH) in advanced/inoperable bladder cancer patients causes significant morbidity. Patients frequently need multiple transfusions. Hypofractionated radiotherapy (RT) has been shown to be effective in symptom palliation. In this study, we explore the efficacy of various fractionation regimens in these patients.</p><p><strong>Methods: </strong>This single institute retrospective analysis was conducted on 60 consecutive patients treated with palliative RT. Fractionation (single versus multiple) and biologically equivalent doses (BED; high ≥36 Gy versus low <36 Gy) were used to compare the efficacy of various fractionation regimens. The primary outcome was the difference in objective response rate (ORR) between various strata at 2, 4, 8 and 12 weeks. Major secondary outcomes were differences in ORR according to Eastern Cooperative Oncology Group (ECOG) performance status (PS) and tumour node metastases (TNM) stage, and the proportion of patients requiring re-transfusion(s) at 12 weeks. Data were analysed using SPSS 23.</p><p><strong>Results: </strong>Overall ORR at 2, 4, 8 and 12 weeks was 86%, 77%, 67% and 55%, respectively. There was no statistically significant difference in response rates between single or multi-fraction, or high versus low BED groups (All <i>p</i> = >0.05). Moreover, ECOG PS (<i>p</i> = 0.11) or TNM stage (<i>p</i> = 0.58) also had no impact on the response rate at 12 weeks. Nearly one-third (31%) of patients required further transfusions at 12 weeks.</p><p><strong>Conclusion: </strong>RT is an effective modality to control GH. No difference in ORR was found between single fractions versus multiple fractions, or high versus low BED regimens. Single fraction RT can be offered to these patients considering low cost, patient convenience and minimal side effects.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1718"},"PeriodicalIF":1.2,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing knowledge, attitude and practice questionnaire in desmoid tumours (KAPID study): applying e-Delphi to rare diseases. 开发类苔藓瘤知识、态度和实践问卷(KAPID 研究):将 e-Delphi 应用于罕见病。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-06-20 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1715
Ghazal Tansir, Sameer Rastogi, Simran Kaur, Mrinal Gounder, Soumya Muta

Background: Rare diseases are associated with unique challenges encountered in diagnosis, treatment and conduct of clinical research. Desmoid tumour (DT) is one such ultra-rare malignancy about which awareness among medical professionals remains limited. We developed a questionnaire to assess knowledge, attitude and practice (KAP) among medical professionals on DT.

Methods: E-Delphi method was used for the assessment of KAP for DT amongst clinical experts (experience of >/= 3 years in DT). 22 open-ended statements were developed by the core research group using current consensus guidelines. In round 1, experts provided subjective feedback which was incorporated into a 35-item questionnaire. Round 2 entailed experts giving feedback as a 5-point Likert scale classified into agreement (median score >/=4), neutral (median score 3) and disagreement (median score <3). Feedback from Round 2 was incorporated and questions with neutral consensus were modified. Questions in Round 3 achieved consensus if >/= 75% participants agreed.

Results: 11 (64.7%) of 17 contacted experts responded in Round 1 including 6 (54.4%) who gave additional inputs and 5 (45.6%) who agreed to all statements. In round 2, 8 out of 11 experts responded to the 35-item questionnaire on knowledge (n = 16), attitude (n = 8) and practice (n = 11). 32 questions obtained agreement and 3 (8.5%) had neutral consensus. These were modified for round 3, in which consensus on 2 (66.6%) was attained. The final questionnaire comprises 34 items with 15, 8 and 11 questions on in the sections of knowledge, attitude and practice (KAP), respectively.

背景:罕见疾病在诊断、治疗和临床研究方面都面临着独特的挑战。蝶形细胞瘤(DT)就是这样一种超罕见恶性肿瘤,医学专业人员对它的认识仍然有限。我们编制了一份调查问卷,以评估医疗专业人员对DT的认识、态度和实践(KAP):采用 E-Delphi 法对临床专家(从事 DT 工作 >/= 3 年)的 DT 知识、态度和实践(KAP)进行评估。在第一轮中,专家们提供了主观反馈,并将其纳入 35 个项目的调查问卷中。第二轮中,专家们以 5 分制李克特量表给出反馈意见,分为同意(中位数>/=4 分)、中立(中位数 3 分)和不同意(中位数 /= 75% 参与者同意):在第一轮中,17 位专家中有 11 位(64.7%)做出了回应,其中 6 位(54.4%)提供了补充意见,5 位(45.6%)同意所有陈述。在第二轮调查中,11 位专家中有 8 位回答了 35 个项目的问卷,涉及知识(16 个)、态度(8 个)和实践(11 个)。32 个问题达成了一致意见,3 个问题(8.5%)达成了中性一致意见。第三轮对这些问题进行了修改,其中 2 个问题(66.6%)达成了共识。最终问卷由 34 个项目组成,知识、态度和实践(KAP)部分分别有 15、8 和 11 个问题。
{"title":"Developing knowledge, attitude and practice questionnaire in desmoid tumours (KAPID study): applying e-Delphi to rare diseases.","authors":"Ghazal Tansir, Sameer Rastogi, Simran Kaur, Mrinal Gounder, Soumya Muta","doi":"10.3332/ecancer.2024.1715","DOIUrl":"10.3332/ecancer.2024.1715","url":null,"abstract":"<p><strong>Background: </strong>Rare diseases are associated with unique challenges encountered in diagnosis, treatment and conduct of clinical research. Desmoid tumour (DT) is one such ultra-rare malignancy about which awareness among medical professionals remains limited. We developed a questionnaire to assess knowledge, attitude and practice (KAP) among medical professionals on DT.</p><p><strong>Methods: </strong>E-Delphi method was used for the assessment of KAP for DT amongst clinical experts (experience of >/= 3 years in DT). 22 open-ended statements were developed by the core research group using current consensus guidelines. In round 1, experts provided subjective feedback which was incorporated into a 35-item questionnaire. Round 2 entailed experts giving feedback as a 5-point Likert scale classified into agreement (median score >/=4), neutral (median score 3) and disagreement (median score <3). Feedback from Round 2 was incorporated and questions with neutral consensus were modified. Questions in Round 3 achieved consensus if >/= 75% participants agreed.</p><p><strong>Results: </strong>11 (64.7%) of 17 contacted experts responded in Round 1 including 6 (54.4%) who gave additional inputs and 5 (45.6%) who agreed to all statements. In round 2, 8 out of 11 experts responded to the 35-item questionnaire on knowledge (<i>n</i> = 16), attitude (<i>n</i> = 8) and practice (<i>n</i> = 11). 32 questions obtained agreement and 3 (8.5%) had neutral consensus. These were modified for round 3, in which consensus on 2 (66.6%) was attained. The final questionnaire comprises 34 items with 15, 8 and 11 questions on in the sections of knowledge, attitude and practice (KAP), respectively.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1715"},"PeriodicalIF":1.2,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy-induced vitiligo in a patient with breast cancer, a case report. 一名乳腺癌患者放疗诱发的白癜风病例报告。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-06-20 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1716
Francisco E Villanueva, Natalia S Jara, Valentina Darlic

Vitiligo is a disease characterised by the autoimmune destruction of melanocytes, manifesting as depigmentation of the skin. We present the case of a female patient with a history of breast cancer who developed vitiligo in the area of the treatment field 12 months after the end of radiotherapy. It has been reported in the literature that vitiligo can occur in patients with a history of vitiligo after radiotherapy, attributable to the Koebner phenomenon, where some treatments can induce new vitiligo lesions in the patient.

白癜风是一种以黑色素细胞自身免疫性破坏为特征的疾病,表现为皮肤色素脱失。本病例中,一名女性患者曾患乳腺癌,在放疗结束 12 个月后,她的治疗区域出现了白癜风。有文献报道,放疗后有白癜风病史的患者可能会出现白癜风,这归因于科布纳现象,即某些治疗可诱发患者出现新的白癜风皮损。
{"title":"Radiotherapy-induced vitiligo in a patient with breast cancer, a case report.","authors":"Francisco E Villanueva, Natalia S Jara, Valentina Darlic","doi":"10.3332/ecancer.2024.1716","DOIUrl":"10.3332/ecancer.2024.1716","url":null,"abstract":"<p><p>Vitiligo is a disease characterised by the autoimmune destruction of melanocytes, manifesting as depigmentation of the skin. We present the case of a female patient with a history of breast cancer who developed vitiligo in the area of the treatment field 12 months after the end of radiotherapy. It has been reported in the literature that vitiligo can occur in patients with a history of vitiligo after radiotherapy, attributable to the Koebner phenomenon, where some treatments can induce new vitiligo lesions in the patient.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1716"},"PeriodicalIF":1.2,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse. 结果一致:波哥大一家四级大学医院的 DLBCL 预后与高收入国家不相上下。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-06-20 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1717
Nicolás Duque Clavijo, Juana Catalina Figueroa Aguirre, Claudia Del Pilar Agudelo Lopez, Andrés Armando Borda, Beatriz Wills, Guillermo Enrique Quintero Vega

Introduction: Diffuse large B-cell lymphoma (DLBCL), a prevalent non-Hodgkin lymphoma subtype, displays diverse clinical outcomes with persistently high mortality and relapse rates, despite treatment advancements. Notably, the Hispanic demographic lacks consideration in existing prognostic indices for DLBCL.

Methods: A retrospective cohort study encompassing 112 DLBCL patients diagnosed between 2010 and 2020 was conducted at our institution. Patient data, including overall survival (OS), treatment response, and relapse, were analysed.

Results: With a median age of 65 years and a predominant male population (60.7%), both the International Prognostic Index (IPI) and revised IPI correlated with OS. In multivariate analysis, patients with ki-67 ≥ 60% exhibited higher mortality risk (Hazard Ratio: 2.35, 95% confidence intervals (CI) 1.05-5.27, p = 0.039), even when controlled by IPI category and B2-microglobulin levels. The absence of B symptoms served as a protective factor for relapse (p < 0.01, OR: 0.147, 95% CI 0.058-0.376) when controlling for ki-67, CD5, and IPI.

Conclusion: Our cohort demonstrated a 5-year OS rate comparable to high-income countries, highlighting the need for tailored prognostic models for Hispanic DLBCL patients. This study identifies easily accessible parameters aligning with regional resource constraints, providing insights into additional prognostic factors for DLBCL in the Hispanic population.

导言:弥漫大B细胞淋巴瘤(DLBCL)是一种常见的非霍奇金淋巴瘤亚型,尽管治疗手段不断进步,但其临床结果却多种多样,死亡率和复发率居高不下。值得注意的是,在现有的 DLBCL 预后指数中缺乏对西班牙裔人群的考虑:我院对2010年至2020年间确诊的112例DLBCL患者进行了回顾性队列研究。研究分析了患者数据,包括总生存期(OS)、治疗反应和复发情况:中位年龄为65岁,男性患者占多数(60.7%),国际预后指数(IPI)和修订后的IPI均与OS相关。在多变量分析中,ki-67≥60%的患者死亡率风险较高(危险比:2.35,95%置信区间(CI)1.05-5.27,p = 0.039),即使与IPI类别和B2-微球蛋白水平对照也是如此。在控制ki-67、CD5和IPI的情况下,无B症状是复发的保护因素(P < 0.01,OR:0.147,95% CI 0.058-0.376):我们的队列显示了与高收入国家相当的5年OS率,突出了为西班牙裔DLBCL患者量身定制预后模型的必要性。这项研究根据地区资源限制确定了易于获得的参数,为西班牙裔人群中DLBCL的其他预后因素提供了见解。
{"title":"Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse.","authors":"Nicolás Duque Clavijo, Juana Catalina Figueroa Aguirre, Claudia Del Pilar Agudelo Lopez, Andrés Armando Borda, Beatriz Wills, Guillermo Enrique Quintero Vega","doi":"10.3332/ecancer.2024.1717","DOIUrl":"10.3332/ecancer.2024.1717","url":null,"abstract":"<p><strong>Introduction: </strong>Diffuse large B-cell lymphoma (DLBCL), a prevalent non-Hodgkin lymphoma subtype, displays diverse clinical outcomes with persistently high mortality and relapse rates, despite treatment advancements. Notably, the Hispanic demographic lacks consideration in existing prognostic indices for DLBCL.</p><p><strong>Methods: </strong>A retrospective cohort study encompassing 112 DLBCL patients diagnosed between 2010 and 2020 was conducted at our institution. Patient data, including overall survival (OS), treatment response, and relapse, were analysed.</p><p><strong>Results: </strong>With a median age of 65 years and a predominant male population (60.7%), both the International Prognostic Index (IPI) and revised IPI correlated with OS. In multivariate analysis, patients with ki-67 ≥ 60% exhibited higher mortality risk (Hazard Ratio: 2.35, 95% confidence intervals (CI) 1.05-5.27, <i>p</i> = 0.039), even when controlled by IPI category and B2-microglobulin levels. The absence of B symptoms served as a protective factor for relapse (<i>p</i> < 0.01, OR: 0.147, 95% CI 0.058-0.376) when controlling for ki-67, CD5, and IPI.</p><p><strong>Conclusion: </strong>Our cohort demonstrated a 5-year OS rate comparable to high-income countries, highlighting the need for tailored prognostic models for Hispanic DLBCL patients. This study identifies easily accessible parameters aligning with regional resource constraints, providing insights into additional prognostic factors for DLBCL in the Hispanic population.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1717"},"PeriodicalIF":1.2,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru. 曲妥珠单抗皮下注射与静脉注射:利用秘鲁一家参考癌症中心的实际数据进行成本最小化分析。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1708
Iris Otoya, Natalia Valdiviezo, Katia Roque, Zaida Morante, Tatiana Vidaurre, Silvia P Neciosup, Mónica J Calderón, Henry L Gomez

Breast cancer (BC) is a global concern, with Peru experiencing a high incidence and mortality. Trastuzumab, a crucial treatment for human epidermal growth factor receptor 2-positive BC, is administered intravenously or subcutaneously (SC). This study evaluates the costs associated with both methods at Peru's Instituto Nacional de Enfermedades Neoplásicas. Real data indicate that SC administration reduces treatment costs by approximately S/15,049.09. Cross-continental comparisons highlight a global trend favouring SC administration for efficiency and cost-effectiveness. The analysis provides insights for informed decision-making in resource-constrained healthcare settings like Peru, emphasising the need to consider local contexts in optimising oncology care.

乳腺癌(BC)是一个全球关注的问题,秘鲁的发病率和死亡率都很高。曲妥珠单抗是治疗人表皮生长因子受体 2 阳性 BC 的重要药物,可通过静脉或皮下注射(SC)给药。这项研究评估了秘鲁国家肿瘤研究所采用这两种方法的相关成本。真实数据显示,皮下注射可减少约 15,049.09 塞舌尔卢比的治疗费用。跨洲比较凸显了一种全球趋势,即在效率和成本效益方面,SC 给药更受青睐。该分析为秘鲁等资源有限的医疗环境提供了明智的决策依据,强调了在优化肿瘤治疗时考虑当地情况的必要性。
{"title":"Subcutaneous versus intravenous administration of Trastuzumab: a minimization cost analysis with real world data from a reference cancer centre in Peru.","authors":"Iris Otoya, Natalia Valdiviezo, Katia Roque, Zaida Morante, Tatiana Vidaurre, Silvia P Neciosup, Mónica J Calderón, Henry L Gomez","doi":"10.3332/ecancer.2024.1708","DOIUrl":"10.3332/ecancer.2024.1708","url":null,"abstract":"<p><p>Breast cancer (BC) is a global concern, with Peru experiencing a high incidence and mortality. Trastuzumab, a crucial treatment for human epidermal growth factor receptor 2-positive BC, is administered intravenously or subcutaneously (SC). This study evaluates the costs associated with both methods at Peru's Instituto Nacional de Enfermedades Neoplásicas. Real data indicate that SC administration reduces treatment costs by approximately S/15,049.09. Cross-continental comparisons highlight a global trend favouring SC administration for efficiency and cost-effectiveness. The analysis provides insights for informed decision-making in resource-constrained healthcare settings like Peru, emphasising the need to consider local contexts in optimising oncology care.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1708"},"PeriodicalIF":1.2,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A dosimetric evaluation of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer in Ghana. 加纳前列腺癌调强放射治疗和三维适形放射治疗的剂量学评估。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1707
Kofi Adesi Kyei, Joseph Daniels, Ameyaw Kwame Adom, Philip Odonkor, Andrew Yaw Nyantakyi, Dorothy Ekua Adjabu

External beam radiotherapy incorporates treatment techniques such as three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), image-guided radiotherapy and volumetric modulated arc therapy to deliver high-energy radiation to cancer. The use of IMRT for cancer treatment is also associated with significant costs for patients in low-middle-income countries. The purpose of this study was to compare the dosimetric properties of 3DCRT and IMRT treatment plans for the external beam irradiation of patients with prostate cancer (Pca) to ascertain the superiority of IMRT in terms of dose homogeneity, conformity and dose limitation to organs at risk (OAR) in a resource-limited setting. One hundred and sixty treatment plans for 80 patients were created using 3DCRT and IMRT on the Eclipse treatment planning system (version 13.6). Data were collected and assessed from the dose-volume histogram of each plan. The conformity and homogeneity index (HI) for each of the plans were calculated. The doses to the OAR were also recorded and evaluated. The mean HIs for the IMRT and 3DCRT treatment techniques were 0.04 ± 0.02 (range: 0.01-0.011) and 0.09 ± 0.02 (range: 0.04-0.016), respectively. The mean conformity index (CI) for IMRT and 3DCRT techniques were 1.257 ± 0.112 (range: 0.99-1.58) and 1.302 ± 0.196 (range: 1.10-2.26). IMRT had a better significant mean HI and CI compared to 3DCRT. Generally, for this study, IMRT had better organ sparing compared to 3DCRT. The mean doses for the OARs ranged from 4.3-74.6 Gy for IMRT and 3.1-75.9 Gy for the 3DCRT technique. Overall, this study demonstrates that IMRT may offer an enhanced therapeutic profile, potentially reducing toxicity to the patient and ensuring more precise dose delivery to the target volume compared to 3DCRT in PCa external beam irradiation.

体外放射治疗结合了三维适形放射治疗(3DCRT)、调强放射治疗(IMRT)、图像引导放射治疗和容积调强弧线治疗等治疗技术,向癌症提供高能量辐射。对于中低收入国家的患者来说,使用 IMRT 治疗癌症也会产生大量费用。本研究的目的是比较 3DCRT 和 IMRT 治疗方案对前列腺癌患者进行体外照射的剂量特性,以确定在资源有限的情况下,IMRT 在剂量均匀性、一致性和对危险器官(OAR)的剂量限制方面的优越性。在 Eclipse 治疗计划系统(13.6 版)上使用 3DCRT 和 IMRT 为 80 名患者创建了 160 个治疗计划。根据每个计划的剂量-体积直方图收集和评估数据。计算每个计划的符合性和均匀性指数(HI)。同时还记录并评估了OAR的剂量。IMRT 和 3DCRT 治疗技术的平均 HI 分别为 0.04 ± 0.02(范围:0.01-0.011)和 0.09 ± 0.02(范围:0.04-0.016)。IMRT和3DCRT技术的平均符合性指数(CI)分别为1.257±0.112(范围:0.99-1.58)和1.302±0.196(范围:1.10-2.26)。与 3DCRT 相比,IMRT 的平均 HI 和 CI 显着性更好。总体而言,在这项研究中,IMRT与3DCRT相比具有更好的器官疏通效果。IMRT的OARs平均剂量为4.3-74.6 Gy,3DCRT技术为3.1-75.9 Gy。总之,这项研究表明,在 PCa 外照射中,与 3DCRT 相比,IMRT 可提供更好的治疗效果,减少对患者的潜在毒性,并确保更精确地将剂量输送到靶区。
{"title":"A dosimetric evaluation of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer in Ghana.","authors":"Kofi Adesi Kyei, Joseph Daniels, Ameyaw Kwame Adom, Philip Odonkor, Andrew Yaw Nyantakyi, Dorothy Ekua Adjabu","doi":"10.3332/ecancer.2024.1707","DOIUrl":"10.3332/ecancer.2024.1707","url":null,"abstract":"<p><p>External beam radiotherapy incorporates treatment techniques such as three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), image-guided radiotherapy and volumetric modulated arc therapy to deliver high-energy radiation to cancer. The use of IMRT for cancer treatment is also associated with significant costs for patients in low-middle-income countries. The purpose of this study was to compare the dosimetric properties of 3DCRT and IMRT treatment plans for the external beam irradiation of patients with prostate cancer (Pca) to ascertain the superiority of IMRT in terms of dose homogeneity, conformity and dose limitation to organs at risk (OAR) in a resource-limited setting. One hundred and sixty treatment plans for 80 patients were created using 3DCRT and IMRT on the Eclipse treatment planning system (version 13.6). Data were collected and assessed from the dose-volume histogram of each plan. The conformity and homogeneity index (HI) for each of the plans were calculated. The doses to the OAR were also recorded and evaluated. The mean HIs for the IMRT and 3DCRT treatment techniques were 0.04 ± 0.02 (range: 0.01-0.011) and 0.09 ± 0.02 (range: 0.04-0.016), respectively. The mean conformity index (CI) for IMRT and 3DCRT techniques were 1.257 ± 0.112 (range: 0.99-1.58) and 1.302 ± 0.196 (range: 1.10-2.26). IMRT had a better significant mean HI and CI compared to 3DCRT. Generally, for this study, IMRT had better organ sparing compared to 3DCRT. The mean doses for the OARs ranged from 4.3-74.6 Gy for IMRT and 3.1-75.9 Gy for the 3DCRT technique. Overall, this study demonstrates that IMRT may offer an enhanced therapeutic profile, potentially reducing toxicity to the patient and ensuring more precise dose delivery to the target volume compared to 3DCRT in PCa external beam irradiation.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1707"},"PeriodicalIF":1.2,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival trends in gastric cancer in Brazil: real-life data from a large cancer center. 巴西胃癌的生存趋势:来自一家大型癌症中心的真实数据。
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-05-30 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1706
Angelo Borsarelli Carvalho Brito, Tiago Cordeiro Felismino, Diego Rodrigues Mendonca E Silva, Maria Paula Curado, Lais Corsino Durant, Rodrigo Gomes Taboada, Adriane Graicer Pelosof, Alessandro Landskron Diniz, Felipe Jose Fernandez Coimbra

Background: Gastric cancer (GC) is the fourth leading cause of cancer deaths globally. There is a paucity of real-life data on GC in Brazil. Our study aimed to evaluate survival trends in gastric adenocarcinoma (GA) in a large cancer center in Brazil during 2000-2017.

Methods: Based on our Hospital Cancer Registry Database, all individuals diagnosed with GA between 2000 and 2017, and treated at A.C. Camargo Cancer Center, were retrospectively included. The primary objectives were to describe the patient demographics, clinicopathological characteristics, treatment modalities and survival trends during four separate periods of diagnosis (2000-2004; 2005-2009; 2010-2014 and 2015-2017). χ2 test was performed between two specified periods (2000-2004 and 2015-2017) to compare categorical variables. Overall survival (OS) curves were stratified by four separate periods and compared with log-rank tests.

Results: This analysis included 1,406 individuals. Across all periods, most patients were men aged 50-69 and presented with Lauren's intestinal subtype. The frequency of stage IV disease significantly decreased between 2000-2004 and 2015-2017 (43.6% to 32.8%, p < 0.001). In contrast, we observed a rise in stage II (9.4% to 24.8%, p < 0.001) in the same comparison. We noticed an increased utilization of a combined approach involving chemotherapy and surgery (12% in 2000-2004 and 36.3% in 2015-2017, p < 0.001). The predicted 5-year OS of patients with GA in 2000-2004 was 27.8%, which increased to 53.9% in 2015-2017 (p < 0.001).

Conclusion: Our retrospective cohort showed an upward trend in survival rates during the period. We observed that 5-year OS almost doubled among men and women during 2000-2017.

Mini abstract: The present retrospective cohort showed an upward trend in survival rates during the period from 2000 to 2017, in which the OS almost doubled among men and women.

背景:胃癌(GC)是全球癌症死亡的第四大原因。巴西有关胃腺癌的真实数据很少。我们的研究旨在评估巴西一家大型癌症中心 2000-2017 年间胃腺癌(GA)的生存趋势:根据我们的医院癌症登记数据库,回顾性纳入了 2000 年至 2017 年期间在 A.C. Camargo 癌症中心接受治疗的所有确诊为胃腺癌的患者。主要目的是描述四个不同诊断时期(2000-2004年;2005-2009年;2010-2014年和2015-2017年)的患者人口统计学特征、临床病理学特征、治疗方式和生存趋势。在两个特定时期(2000-2004年和2015-2017年)之间进行χ2检验,以比较分类变量。总生存率(OS)曲线按四个不同时期进行分层,并用对数秩检验进行比较:该分析包括 1 406 人。在所有时期中,大多数患者为 50-69 岁的男性,表现为劳伦肠亚型。2000-2004 年至 2015-2017 年间,IV 期疾病的发病率明显下降(43.6% 降至 32.8%,p < 0.001)。相比之下,我们观察到 II 期患者的比例在同一时期有所上升(从 9.4% 上升至 24.8%,p < 0.001)。我们注意到,化疗和手术联合疗法的使用率有所上升(2000-2004年为12%,2015-2017年为36.3%,P<0.001)。2000-2004年,GA患者的预测5年OS为27.8%,2015-2017年增至53.9%(P < 0.001):我们的回顾性队列显示,这一时期的生存率呈上升趋势。我们观察到,2000-2017年间,男性和女性的5年OS几乎翻了一番。小结:本回顾性队列显示,2000-2017年间,生存率呈上升趋势,其中男性和女性的OS几乎翻了一番。
{"title":"Survival trends in gastric cancer in Brazil: real-life data from a large cancer center.","authors":"Angelo Borsarelli Carvalho Brito, Tiago Cordeiro Felismino, Diego Rodrigues Mendonca E Silva, Maria Paula Curado, Lais Corsino Durant, Rodrigo Gomes Taboada, Adriane Graicer Pelosof, Alessandro Landskron Diniz, Felipe Jose Fernandez Coimbra","doi":"10.3332/ecancer.2024.1706","DOIUrl":"10.3332/ecancer.2024.1706","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is the fourth leading cause of cancer deaths globally. There is a paucity of real-life data on GC in Brazil. Our study aimed to evaluate survival trends in gastric adenocarcinoma (GA) in a large cancer center in Brazil during 2000-2017.</p><p><strong>Methods: </strong>Based on our Hospital Cancer Registry Database, all individuals diagnosed with GA between 2000 and 2017, and treated at A.C. Camargo Cancer Center, were retrospectively included. The primary objectives were to describe the patient demographics, clinicopathological characteristics, treatment modalities and survival trends during four separate periods of diagnosis (2000-2004; 2005-2009; 2010-2014 and 2015-2017). <i>χ</i>2 test was performed between two specified periods (2000-2004 and 2015-2017) to compare categorical variables. Overall survival (OS) curves were stratified by four separate periods and compared with log-rank tests.</p><p><strong>Results: </strong>This analysis included 1,406 individuals. Across all periods, most patients were men aged 50-69 and presented with Lauren's intestinal subtype. The frequency of stage IV disease significantly decreased between 2000-2004 and 2015-2017 (43.6% to 32.8%, <i>p</i> < 0.001). In contrast, we observed a rise in stage II (9.4% to 24.8%, <i>p</i> < 0.001) in the same comparison. We noticed an increased utilization of a combined approach involving chemotherapy and surgery (12% in 2000-2004 and 36.3% in 2015-2017, <i>p</i> < 0.001). The predicted 5-year OS of patients with GA in 2000-2004 was 27.8%, which increased to 53.9% in 2015-2017 (<i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Our retrospective cohort showed an upward trend in survival rates during the period. We observed that 5-year OS almost doubled among men and women during 2000-2017.</p><p><strong>Mini abstract: </strong>The present retrospective cohort showed an upward trend in survival rates during the period from 2000 to 2017, in which the OS almost doubled among men and women.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1706"},"PeriodicalIF":1.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya. 肯尼亚一家三级转诊医院胰腺癌患者的临床病理特征和治疗效果。
IF 1.8 Q4 ONCOLOGY Pub Date : 2024-03-19 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1682
Sheila W Muchiri, Elly O Ogutu, Peter O Oyiro, Lars Aabakken

The global incidence of pancreatic cancer (PC) continues to steadily increase whereas its prognosis remains poor. Previous studies have suggested worse outcomes among individuals of African descent. The characteristics of patients with PC in Kenya, and their contemporary management and survival outcomes remain largely unknown. This study aimed to describe the clinical and pathologic characteristics, management, and outcomes of patients diagnosed with PC at Kenyatta National Hospital (KNH), a tertiary referral hospital in Kenya. Records of 242 patients diagnosed with PC at KNH between 1st January 2014 and 30th September 2021 were assessed in this retrospective cohort study. Data on their clinical, histopathologic, and treatment characteristics was presented as mean (± standard deviation) and/or median (interquartile range) for continuous variables and frequency (percentage) for categorical variables. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis. PC occurred in a young population, the median age being 58.5 years (inter-quartile range 35-88). The majority of tumours (54%) were metastatic at diagnosis, while 28% and 14% were stage III and stage I/II, respectively. Surgical resections with curative intent were performed on 7% overall and 44% of stage I/II cases. The majority of patients with stage I/II disease (52.9%) received chemotherapy whereas the majority with stage III and IV disease received the best supportive care only (62.7% and 64.9%, respectively). Patients who underwent surgical resection (HR for mortality 0.20, 95% CI 0.05-0.83, p = 0.021) and chemotherapy (HR for mortality 0.15, 95% CI 0.08-0.29, p < 0.001) had significantly improved survival, reflecting a more favourable stage of the disease more amenable to aggressive therapies. The median survival time was 3 months and the 1-year survival rate was 32%.

胰腺癌(PC)的全球发病率持续稳步上升,但其预后仍然很差。以往的研究表明,非洲裔患者的预后较差。肯尼亚胰腺癌患者的特征以及他们的现代管理和生存结果在很大程度上仍不为人所知。本研究旨在描述肯尼亚三级转诊医院肯雅塔国立医院(KNH)确诊的 PC 患者的临床和病理特征、管理和预后情况。在这项回顾性队列研究中,对2014年1月1日至2021年9月30日期间在肯雅塔国立医院确诊的242名PC患者的记录进行了评估。连续变量的临床、组织病理学和治疗特征数据以均值(± 标准差)和/或中位数(四分位数间距)表示,分类变量的数据以频率(百分比)表示。生存分析采用卡普兰-梅耶尔和考克斯比例危险比。PC发生在年轻人群中,中位年龄为58.5岁(四分位数间距为35-88岁)。大多数肿瘤(54%)在确诊时已转移,28%和14%的肿瘤分别处于III期和I/II期。7%的患者接受了根治性手术切除,44%的I/II期患者接受了根治性手术切除。大多数 I/II 期患者(52.9%)接受了化疗,而大多数 III 期和 IV 期患者只接受了最佳支持治疗(分别为 62.7% 和 64.9%)。接受手术切除(死亡率HR为0.20,95% CI为0.05-0.83,p = 0.021)和化疗(死亡率HR为0.15,95% CI为0.08-0.29,p < 0.001)的患者生存率明显提高,这反映出患者的病情处于更有利的阶段,更适合接受积极的治疗。中位生存时间为3个月,1年生存率为32%。
{"title":"Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya.","authors":"Sheila W Muchiri, Elly O Ogutu, Peter O Oyiro, Lars Aabakken","doi":"10.3332/ecancer.2024.1682","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1682","url":null,"abstract":"<p><p>The global incidence of pancreatic cancer (PC) continues to steadily increase whereas its prognosis remains poor. Previous studies have suggested worse outcomes among individuals of African descent. The characteristics of patients with PC in Kenya, and their contemporary management and survival outcomes remain largely unknown. This study aimed to describe the clinical and pathologic characteristics, management, and outcomes of patients diagnosed with PC at Kenyatta National Hospital (KNH), a tertiary referral hospital in Kenya. Records of 242 patients diagnosed with PC at KNH between 1st January 2014 and 30th September 2021 were assessed in this retrospective cohort study. Data on their clinical, histopathologic, and treatment characteristics was presented as mean (± standard deviation) and/or median (interquartile range) for continuous variables and frequency (percentage) for categorical variables. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis. PC occurred in a young population, the median age being 58.5 years (inter-quartile range 35-88). The majority of tumours (54%) were metastatic at diagnosis, while 28% and 14% were stage III and stage I/II, respectively. Surgical resections with curative intent were performed on 7% overall and 44% of stage I/II cases. The majority of patients with stage I/II disease (52.9%) received chemotherapy whereas the majority with stage III and IV disease received the best supportive care only (62.7% and 64.9%, respectively). Patients who underwent surgical resection (HR for mortality 0.20, 95% CI 0.05-0.83, p = 0.021) and chemotherapy (HR for mortality 0.15, 95% CI 0.08-0.29, p < 0.001) had significantly improved survival, reflecting a more favourable stage of the disease more amenable to aggressive therapies. The median survival time was 3 months and the 1-year survival rate was 32%.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1682"},"PeriodicalIF":1.8,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chest wall perforator flap partial breast reconstruction: a retrospective analysis of surgical, cosmetic and survival outcome. 胸壁穿孔器皮瓣部分乳房重建:手术、美容和存活效果的回顾性分析。
IF 1.8 Q4 ONCOLOGY Pub Date : 2024-03-14 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1681
Sanjit Kumar Agrawal, Shagun Mahajan, Rosina Ahmed, Neela Shruti, Abhishek Sharma

Introduction: Oncoplastic breast surgery includes volume replacement as well as volume displacement. Autologous tissue is the preferred approach for volume replacement and includes chest wall perforator flaps (CWPF). Although described more than a decade ago, CWPFs have not been adopted widely in clinical practice till recently. We report the largest single-centre institutional data on CWPFs.

Patients and methods: The study includes all patients who underwent breast conservation surgery (BCS) using CWPFs from January 2015 to December 2022. Data were retrieved from the institutional electronic record and Redcap database. The analysis was done using SPSS 23 and STATA 14.

Results: 150 patients were included in the study. The mean age was 48.8 years (SD 10.4), and the body mass index was (26.6 kg/m2, SD 4.3). >50% of patients had breasts with small cup sizes (A&B) and mild ptosis (Non-ptotic and Grade 1 ptosis). 44.7% of patients underwent lateral intercostal artery perforator flap (LICAP), anterior intercostal artery perforator flap in 31.3%, lateral thoracic perforator flap (LTAP) in 12%, LICAP + LTAP in 11.3% and thoracodorsal artery perforator flap in 1%. Post-operatively, haematoma was seen in 1.3%, complete flap necrosis in 1.3%, seroma in 7%, wound dehiscence in 12%, and positive margin in 6.7%. 92 patients responded to the satisfaction assessment, of which >90% were happy with the surgical scars, comfortable going out in a public place, satisfied with the symmetry of the breast, and no one chose mastectomy in hindsight. The 5-year predicted disease free survival and overall survival were 86.4% and 94.7%, respectively.

Conclusion: BCS with CWPF is an excellent option for reconstruction in small to medium-sized breasts. It is associated with minimal morbidity and comparable patient-reported cosmetic and survival outcomes.

简介:肿瘤整形乳房手术包括容积置换和容积置换:肿瘤整形乳房手术包括体积置换和体积移位。自体组织是体积置换的首选方法,包括胸壁穿孔器皮瓣(CWPF)。虽然 CWPF 早在十多年前就被描述过,但直到最近才在临床实践中被广泛采用。我们报告了有关 CWPFs 的最大单中心机构数据:研究对象包括2015年1月至2022年12月期间使用CWPFs进行保乳手术(BCS)的所有患者。数据取自机构电子记录和Redcap数据库。使用 SPSS 23 和 STATA 14 进行分析:研究共纳入 150 名患者。平均年龄为 48.8 岁(SD 10.4),体重指数为(26.6 kg/m2,SD 4.3)。>50%以上的患者的乳房为小罩杯(A&B)和轻度上睑下垂(非上睑下垂和 1 级上睑下垂)。44.7%的患者接受了肋间外侧动脉穿孔器皮瓣(LICAP),31.3%的患者接受了肋间前动脉穿孔器皮瓣,12%的患者接受了胸廓外侧穿孔器皮瓣(LTAP),11.3%的患者接受了LICAP + LTAP,1%的患者接受了胸背动脉穿孔器皮瓣。术后出现血肿的占 1.3%,皮瓣完全坏死的占 1.3%,血清肿的占 7%,伤口开裂的占 12%,边缘阳性的占 6.7%。92名患者接受了满意度评估,其中90%以上的患者对手术疤痕感到满意,在公共场所外出时感到舒适,对乳房的对称性感到满意,没有人在事后选择切除乳房。5年预测无病生存率和总生存率分别为86.4%和94.7%:结论:带CWPF的BCS是中小型乳房重建的绝佳选择。结论:采用 CWPF 的 BCS 是中小型乳房重建的绝佳选择,其发病率极低,患者报告的美容效果和存活率相当。
{"title":"Chest wall perforator flap partial breast reconstruction: a retrospective analysis of surgical, cosmetic and survival outcome.","authors":"Sanjit Kumar Agrawal, Shagun Mahajan, Rosina Ahmed, Neela Shruti, Abhishek Sharma","doi":"10.3332/ecancer.2024.1681","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1681","url":null,"abstract":"<p><strong>Introduction: </strong>Oncoplastic breast surgery includes volume replacement as well as volume displacement. Autologous tissue is the preferred approach for volume replacement and includes chest wall perforator flaps (CWPF). Although described more than a decade ago, CWPFs have not been adopted widely in clinical practice till recently. We report the largest single-centre institutional data on CWPFs.</p><p><strong>Patients and methods: </strong>The study includes all patients who underwent breast conservation surgery (BCS) using CWPFs from January 2015 to December 2022. Data were retrieved from the institutional electronic record and Redcap database. The analysis was done using SPSS 23 and STATA 14.</p><p><strong>Results: </strong>150 patients were included in the study. The mean age was 48.8 years (SD 10.4), and the body mass index was (26.6 kg/m<sup>2</sup>, SD 4.3). >50% of patients had breasts with small cup sizes (A&B) and mild ptosis (Non-ptotic and Grade 1 ptosis). 44.7% of patients underwent lateral intercostal artery perforator flap (LICAP), anterior intercostal artery perforator flap in 31.3%, lateral thoracic perforator flap (LTAP) in 12%, LICAP + LTAP in 11.3% and thoracodorsal artery perforator flap in 1%. Post-operatively, haematoma was seen in 1.3%, complete flap necrosis in 1.3%, seroma in 7%, wound dehiscence in 12%, and positive margin in 6.7%. 92 patients responded to the satisfaction assessment, of which >90% were happy with the surgical scars, comfortable going out in a public place, satisfied with the symmetry of the breast, and no one chose mastectomy in hindsight. The 5-year predicted disease free survival and overall survival were 86.4% and 94.7%, respectively.</p><p><strong>Conclusion: </strong>BCS with CWPF is an excellent option for reconstruction in small to medium-sized breasts. It is associated with minimal morbidity and comparable patient-reported cosmetic and survival outcomes.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1681"},"PeriodicalIF":1.8,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emergence of telemedicine in a low-middle-income country: challenges and opportunities. 远程医疗在中低收入国家的兴起:挑战与机遇。
IF 1.8 Q4 ONCOLOGY Pub Date : 2024-03-01 eCollection Date: 2024-01-01 DOI: 10.3332/ecancer.2024.1679
Kofi Adesi Kyei, George Nakoja Onajah, Joseph Daniels

The quality of cancer care delivery varies across different regions of Ghana, highlighting the need for improved access to quality healthcare services. Telemedicine has emerged as a promising solution to address this disparity, as it can reduce costs and improve access to healthcare services for cancer patients in remote areas. Despite the widely reported benefits of telemedicine, its adoption in low-resource settings has been slow due to several challenges. This study explores strategies for incorporating telemedicine into the current healthcare system in Ghana for the benefit of all patients especially those diagnosed with cancer. The study also highlights the current challenges and opportunities associated with the implementation and utilisation of telemedicine in Ghana. This research was a cross-sectional study conducted in Accra, Ghana that adopted a mixed-methods approach. Participants were selected through multi-stage probability sampling. Quantitative data were collected via a survey whereas qualitative data were obtained by means of in-depth interviews and focus group discussions among healthcare professionals, patients and key stakeholders in the telemedicine industry. The Statistical Program for the Social Sciences (version 21) was used to assemble, analyse and display the research data. The major challenges discussed centered on high initial investment costs, privacy and security concerns, poor internet connectivity, insufficient infrastructure and training of healthcare providers as well as the resistance to change among healthcare professionals. The study contributes to the understanding of telemedicine adoption in Ghana with findings underscoring the potential to address healthcare challenges while highlighting the need to overcome implementation obstacles. The study findings also provide valuable insights for policymakers, healthcare institutions and stakeholders to enhance telemedicine adoption in Ghana.

加纳不同地区的癌症治疗质量参差不齐,这凸显了改善优质医疗服务获取途径的必要性。远程医疗可以降低成本,改善偏远地区癌症患者获得医疗服务的机会,因此已成为解决这种差异的一种有前途的解决方案。尽管远程医疗的好处被广泛报道,但由于存在一些挑战,其在低资源环境中的应用一直进展缓慢。本研究探讨了将远程医疗纳入加纳现有医疗系统的策略,以造福所有患者,尤其是确诊为癌症的患者。研究还强调了加纳目前在实施和利用远程医疗方面所面临的挑战和机遇。本研究是一项横断面研究,在加纳阿克拉进行,采用了混合方法。参与者是通过多阶段概率抽样选出的。定量数据通过调查收集,而定性数据则通过对医疗保健专业人员、患者和远程医疗行业主要利益相关者的深入访谈和焦点小组讨论获得。研究使用了社会科学统计程序(第 21 版)来汇总、分析和显示研究数据。所讨论的主要挑战集中在初期投资成本高、隐私和安全问题、互联网连接性差、基础设施不足、医疗服务提供者的培训以及医疗专业人员对变革的抵制。这项研究有助于了解加纳采用远程医疗的情况,研究结果强调了应对医疗挑战的潜力,同时也强调了克服实施障碍的必要性。研究结果还为政策制定者、医疗机构和利益相关者提供了宝贵的见解,以促进远程医疗在加纳的应用。
{"title":"The emergence of telemedicine in a low-middle-income country: challenges and opportunities.","authors":"Kofi Adesi Kyei, George Nakoja Onajah, Joseph Daniels","doi":"10.3332/ecancer.2024.1679","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1679","url":null,"abstract":"<p><p>The quality of cancer care delivery varies across different regions of Ghana, highlighting the need for improved access to quality healthcare services. Telemedicine has emerged as a promising solution to address this disparity, as it can reduce costs and improve access to healthcare services for cancer patients in remote areas. Despite the widely reported benefits of telemedicine, its adoption in low-resource settings has been slow due to several challenges. This study explores strategies for incorporating telemedicine into the current healthcare system in Ghana for the benefit of all patients especially those diagnosed with cancer. The study also highlights the current challenges and opportunities associated with the implementation and utilisation of telemedicine in Ghana. This research was a cross-sectional study conducted in Accra, Ghana that adopted a mixed-methods approach. Participants were selected through multi-stage probability sampling. Quantitative data were collected via a survey whereas qualitative data were obtained by means of in-depth interviews and focus group discussions among healthcare professionals, patients and key stakeholders in the telemedicine industry. The Statistical Program for the Social Sciences (version 21) was used to assemble, analyse and display the research data. The major challenges discussed centered on high initial investment costs, privacy and security concerns, poor internet connectivity, insufficient infrastructure and training of healthcare providers as well as the resistance to change among healthcare professionals. The study contributes to the understanding of telemedicine adoption in Ghana with findings underscoring the potential to address healthcare challenges while highlighting the need to overcome implementation obstacles. The study findings also provide valuable insights for policymakers, healthcare institutions and stakeholders to enhance telemedicine adoption in Ghana.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1679"},"PeriodicalIF":1.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ecancermedicalscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1